Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial
Frederick W Reimherr1, Dawson W Hedges, Robert E Strong
1University of Utah, Department of Psychiatry Salt Lake City, UT, USA. fred.reimherr@hsc.utah.edu
Abstract:
Increased attention has been given to the alternatives to stimulants in the treatment of attention deficit hyperactivity disorder (ADHD) in both adults and children. This short-term, double-blind trial was designed to evaluate the extended-release form of bupropion in adult subjects meeting DSM-IV and the Utah Diagnostic Criteria for ADHD. Outcome measures were the Clinical Global Impressions-Improvement (CGI-I) and the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS), which assesses adult ADHD symptoms. Outcome (defined by the CGI-I, average WRAADDS scores, or a 50% improvement on the WRAADDS) favored bupropion SR over placebo, but achieved statistical significance on only one, post hoc measure. Other measures showed trends for improvement with bupropion. Given the small size of this study, these findings deserve further exploration.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Oral Drug Delivery Systems: Continuous-Release Systems
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Anxiolytic Drugs: Benzodiazepines and Buspirone

